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Abstract 
The management of patients with brain metastases has become a major issue due to the 
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, 
the European Association of Neuro-Oncology (EANO) created a multidisciplinary Task Force 
to draw evidence-based guidelines for patients with brain metastases from solid tumors. Here, 
we present these Guidelines, which provide a consensus review of evidence and 
recommendations for diagnosis by neuroimaging and neuropathology, staging, prognostic 
factors, and different treatment options. Specifically, we addressed options, such as surgery, 
stereotactic radiosurgery/stereotactic fractionated radiotherapy, whole-brain radiotherapy, 
chemotherapy and targeted therapy (with particular attention to brain metastases from NSCLC, 
melanoma, breast and renal cancer), and supportive care.  
 
Key Words   
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Stereotactic Fractionated Radiotherapy, Whole-Brain Radiation Therapy, Chemotherapy, 
Targeted Therapy, Supportive Care. 
 
Running title: EANO Guidelines on Brain metastases 
 
Importance of the Study 
This manuscript reports the evidence-based guidelines on management of brain metastases 
developed by a multidisciplinary Task Force of the European Association of Neuro-Oncology 
(EANO), composed of medical experts from 10 European  countries, including neurologists, 
neurosurgeons, radiation oncologists, medical oncologists, neuroradiologists and 
neuropathologists. These Guidelines should aid all professionals involved in the management 
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of patients with brain metastases in the daily clinical practice, and could also serve as a source 
of knowledge for institutions and insurance companies involved in cancer care in Europe.     
 
Introduction 
Brain metastases represent a common neurological complication of systemic cancer and are an 
important cause of morbidity and mortality.  
Brain metastases are the most frequent intracranial tumors: the incidence of newly diagnosed 
brain metastases is 3-10 times the incidence of newly diagnosed primary malignant brain 
tumors
1
. The incidence of brain metastases has increased over time, as a result of increasing 
use of neuroimaging and improvement in the treatment of systemic disease.  
The majority of patients who develop brain metastases have a limited life expectancy, as the 
appearance of the disease in the brain is frequently a hallmark of disseminated end stage 
disease, but patients with a limited disease may have a more favorable outcome with the use of 
intensive therapies. The knowledge of the most powerful prognostic factors (Karnofsky 
Performance Status- KPS, age, extracranial tumor activity, number of brain metastases, 
primary tumor type/molecular subtype) is crucial for predicting the individual prognosis. In 
this regard, several prognostic indices have been develop in order to distinguish subgroups of 
patient with different outcome 
2,3
. 
The objective of this Guideline is to provide clinicians with evidence-based recommendations 
and consensus expert opinion for the management of adult patients with brain metastases from 
solid tumors.  
The search strategy and selection criteria for reviewing the literature evidence can be found in 
the Table 1. 
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Diagnostic approach 
Diagnosis by neuroimaging, Staging and Diagnostic neuropathology have been reviewed but 
not graded. These sections can be found in the Supplementary Material. 
 
Treatment of newly diagnosed brain metastasis 
Surgery 
Three phase III trials have compared surgical resection followed by whole brain radiotherapy 
(WBRT) with WBRT alone in patients with in single brain metastases 
4-6
. 
The first two studies, both of which were underpowered, reported a survival benefit for 
patients receiving the combined treatment (median survival 10 months vs 4-6 months). In the 
Patchell’s study, patients who received surgery had a lower rate of brain relapses (20% versus 
52%) and a longer time of functional independence. The third study, which included more 
patients with an active systemic disease (80% vs 30-40%) and a lower Karnofsky performance 
status, did not show benefit with the addition of surgery to WBRT 
6
. However, a considerable 
fraction of patients assigned to WBRT alone actually crossed over to receive surgery, and this 
may have contributed to similar survival between the 2 treatment arms. None of the patients 
had pre-treatment MRI-scans, thus inclusion of patients with multiple brain metastases could 
not be excluded. Overall, the study was poorly designed and executed, making it less 
informative. In summary, there is limited class I evidence for survival benefit of surgical 
resection in addition to WBRT, and this is likely to be restricted to the subgroup of patients 
with controlled systemic disease and good performance status.  
Surgical resection allows in the majority of patients an immediate relief of symptoms of 
intracranial hypertension, a reduction of focal neurological deficits and seizures, and a rapid 
steroid taper. Gross total resection of a brain metastasis can be achieved with lower morbidity 
using contemporary image guided systems, such as preoperative functional MRI, 
intraoperative neuronavigation and cortical mapping (class IV) 
7
. An early postoperative MRI  
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has been reported to detect residual tumor in up to 20% of patients, and the presence of 
residual tumor has been associated with an increased risk of local recurrence (class IIIb) 
8
. 
The impact of surgical techniques on the complication rate and functional outcome as well as 
on the risk of local relapse in patients with single brain metastasis has been recently reviewed 
(class IIIb) 
9
. Leptomeningeal dissemination (LMD) can be a complication, especially in 
patients with posterior fossa metastases undergoing a “piecemeal” resection (13.8%) compared 
with “en bloc” resection (5% - 6%) (class IIIb) 10. 
In patients with 2 or 3 brain metastases, who have a high performance status and controlled 
systemic disease, complete surgical resection yields results that are comparable to those 
obtained in single lesions (class IIIb) 
11
. 
Stereotactic radiosurgery 
Stereotactic radiosurgery (SRS) is a high precision localized irradiation given in one fraction 
using a combination of firm immobilization and image guidance. Convergence of multiple 
static or moving beams achieves a steep dose fall-off from the target to the surrounding normal 
structures allowing for a high dose to the tumor with low risk of damage to surrounding 
normal brain. Small brain metastases represent an ideal target for SRS, owing to the generally 
spherical shape, and distinct pathologic margins 
12
. The dose is inversely related to tumor size. 
Maximal tolerated doses of SRS have been described in RTOG 9005 study 
13
, which included 
heterogeneous groups of patients with previously irradiated primary brain tumors and brain 
metastases. The suggested doses were  24 Gy for ≤ 20 mm, 18 Gy for 21-30 mm and 15 Gy for 
31-40 mm in maximum diameter lesions. High single radiation doses to large tumours or 
tumours close to critical neural structures are associated with significant risk of toxicity, and 
there are attempts at employing hypofractionated regimens to achieve adequate local control 
with acceptable toxicity. However, randomized studies comparing stereotactic fractionated 
radiotherapy (SFRT) versus single dose SRS are lacking.  
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Single dose SRS in the treatment of a limited number (1-3) of newly diagnosed brain 
metastases has yielded a local control (defined as shrinkage or arrest of growth) at 1 year of 
80%-90 % with symptoms improvement and median survival of 6-12 months (class IIIa) 
14
. 
Patients with a single lesion, controlled extracranial disease and KPS of 70% or greater have 
longer survival 
15,16
. Metastases from radioresistant tumors, such as melanoma and renal cell 
carcinoma, respond to SRS as do metastases from radiosensitive tumors 
17
. Older patients (≥ 
80 years of age) respond as well as younger patients 
18
. The outcome following gamma-knife 
or linear accelerator (Linac)-based procedures is similar.  
A randomized phase III study (RTOG 9508) in patients with 1-3 brain metastases, stratified by 
the RPA prognostic classification, investigated the value of the addition of a SRS boost to 
WBRT 
19
, and reported better local control and performance status at 6 months in the 
combined therapy group (class I) ; however, the survival advantage was only demonstrated in 
patients with single metastasis (6.5 months vs 4.9 months). A secondary analysis of RTOG 
9508, that retrospectively stratified patients with the GPA prognostic classification, suggested 
that the addition of SRS to WBRT confers a significant survival benefit for patients with a 
good prognosis (GPA 3.5-4.0) regardless of whether they had 1, 2 or 3 brain metastases 
20
. 
Conversely, this benefit did not extend to patients with lower GPA and/or 2-3 metastases.. 
In the past 5-10 years SRS has been increasingly used for patients with higher number of brain 
metastases, due to improved technology that allows the delivery of SRS with increasing speed 
while maintaining precision and accurancy. A prospective multicenter Japanese study 
investigated the use of SRS alone in 1194 patients with 1, 2 to 4 or 5 to 10 brain metastases, 
and found similar overall survival (10.8 months) and treatment related toxicity rates between 
the groups with 2 to 4 and 5 to 10 metastases (class IIIa) 
16
. Cumulative volume of metastases, 
rather than the number, was reported as a significant prognostic factor 
16
.  
Early, early delayed and late complications following radiosurgery are reported in 10-40% of 
patients, but serious complications are rare 
21
, although this may be a function of limited 
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follow up. Acute reactions presumed to be due to edema can occur within 2 weeks of treatment 
and consist of headache, nausea and vomiting, worsening of pre-existent neurological deficits 
and seizures. These reactions are generally reversible with steroids. Late complications 
(months to years) consist of hemorrhage and radionecrosis and have been reported in 1–17% 
of patients. Following SRS treatment-related changes, such as increase of contrast 
enhancement, necrosis, edema and mass effect on MRI are difficult to distinguish from tumor 
progression: in this regard, PET with FDG or amino acids, MRI perfusion and MR 
spectroscopy may provide additional information though are rarely diagnostic 
22
. 
Radiation necrosis is commonly treated with steroids. Hyperbaric oxygen and/or the anti-
VEGF agent bevacizumab, which may allow stabilization/normalization of the vascular 
permeability, can be useful   in patients not responding to steroids 
23
. Surgical resection is 
needed in some patients. 
The risk of adverse radiation effects following SRS has been reported to increase with the 
increase of size of lesions with a 1 year cumulative incidence of 13-14% 
24
. A wide range in 
the time of onset and time to improvement of these effects was observed. 
There are no reports in the literature on the treatment of brain metastases with proton 
radiosurgery 
25
. 
Surgery vs Stereotactic Radiosurgery 
Most studies comparing surgery and SRS report similar outcomes: however, they are not 
randomized and likely to be affected by selection bias (class IIIb) 
26,28
. 
SRS is considered less invasive, can be carried out in an outpatient setting, and is more cost-
effective than surgery. On the other hand, Patients with larger lesions may require chronic 
steroid administration.  
Whole Brain Radiotherapy following Surgery or Stereotactic Radiosurgery  
There has been a long debate as to whether adjuvant WBRT, whose rationale is that of 
destroying microscopic disease at original tumor site or at distant intracranial locations, is 
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necessary after complete surgical resection or radiosurgery of a limited number of brain 
metastases 
29,30
.  
Three large phase III trials 
31-33
 and a metanalysis 
34
 have been carried out. They demonstrated 
that the omission of WBRT in patients with a limited number of brain metastases after either 
complete surgery or SRS results in significantly worse local and distant control in the brain, 
but does not affect functionally independent and overall survival (class I). The American 
31
 
and the Japanese 
32
 trials included patients with both stable and progressive systemic disease, 
while the European  trial 
33
 was restricted to patients with stable systemic disease, i.e. those 
who could maximally benefit in terms of survival from improved intracranial control. A recent 
individual patient data meta-analysis of three randomized trials comparing SRS alone with 
SRS + WBRT in patients with 1 to 4  brain metastases [35] suggested a survival advantage for 
SRS alone in patients aged < 50 years without a reduction in the risk of new brain metastases 
with adjuvant WBRT; conversely, in patients aged > 50 years WBRT decreased the risk of 
new brain metastases but did not affect survival. A secondary analysis of the Japanese trial has 
retrospectively stratified patients by GPA score and suggested that a subgroup of patients with 
NSCLC with higher GPA scores (2.5-4.0) has a survival benefit from SRS+WBRT compared 
to SRS alone (median survival 16.7 vs 10.7 months) 
36
. These are exploratory hypotheses, 
which require further studies. 
Adjuvant WBRT following surgery reduces local and distant recurrences in the brain among 
patients with metastases ˃ 3 cm and/or active systemic disease (class IIIb) 37. 
The impact of adjuvant WBRT on cognitive functions and quality of life has been analyzed in 
few studies. Aoyama et al 
38
 compared the neurocognitive function of patients who underwent 
SRS alone or SRS + WBRT. More than 50% of patients experienced a significant 
improvement in MMSE score shortly after therapy (2-3 months) regardless of which treatment 
they had initially received, with subsequent deterioration of neurocognitive function in long-
term survivors (up to 36 months) after WBRT. Chang et al 
39
 in a small randomized trial have 
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shown that patients treated with SRS plus WBRT were at greater risk of a decline in learning 
and memory function at 4 months after treatment compared with those receiving SRS alone. 
A randomized phase III trial (Alliance trial) has compared SRS alone versus SRS + WBRT in 
patients with 1-3 brain metastases using a primary neurocognitive endpoint, defined as decline 
from baseline in any six cognitive tests at 3 months 
40
. The decline was significantly more 
frequent after SRS + WBRT vs SRS alone (88% vs 61.9%) (class I) with more deterioration in 
immediate recall (31% vs 8%), delayed recall (51% vs 20%) and verbal fluency (19% vs 2%). 
A quality of life analysis of the EORTC 22952-26001 trial has shown over 1 year of follow up 
no significant differences in the global Health Related Quality of Life, but patients undergoing 
adjuvant WBRT had transient lower physical functioning and cognitive functioning scores and 
more fatigue (class I) 
41
. 
Based on the results of these trials, the American Society for Radiation Oncology (ASTRO) 
has recommended in their Choose Wisely campaign not to routinely add adjuvant WBRT to 
SRS for patients with limited number of brain metastases. 
The issue of the need of WBRT following surgical resection is less well defined, as the 
randomized trials reported an increased risk of local relapse following surgery alone, though it 
remains unclear whether an active surveillance with salvage local therapy is as effective as an 
early additional treatment in the form of WBRT. 
Stereotactic radiosurgery/Stereotactic fractionated radiotherapy following surgery 
Postoperative SRS is an approach to decrease the local relapse following surgery, while 
avoiding the cognitive sequelae of WBRT. Several retrospective 
42-44
 and one prospective 
phase II trials 
45
 reported local control rates at 1 year around 80% (70%-90%) and a median 
survival of 10-17 months (class IIIa): this suggests that postoperative SRS is as effective as 
WBRT in achieving local control. An alternative approach is the use of stereotactic 
fractionated radiotherapy (SFRT) presumed to be associated with lower risk of radionecrosis 
in larger lesions 
44,46
.  
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The balance between risk and benefit is currently unknown with unsolved issues, such as the 
optimal dose and fractionation, the effects on survival, QoL, and cognitive funtion. 
Randomized trials are ongoing. 
The risk of radionecrosis following postoperative SRS seems higher (9% - 17.5%) 
47,48
 than 
that reported by the EORTC study with WBRT following either surgery or radiosurgery 
(2.6%), and could increase over time (7% at 1 year and 16% at 2 years).  
There is lack of information on the clinical counterparts of radionecrosis, and on the incidence 
of acute complications of SRS, such as seizures, headache and hemorrhage. One of the risks 
following SRS is the steroid dependency to control chronic edema: so far, both frequency and 
duration of steroid use following postoperative SRS have not been analyzed. 
SRS to the resection cavity is associated with a risk of leptomeningeal relapse in 8% to 13% of 
patients 
49,50
, especially with breast histology (at 1 year 24% versus 9%): it is unknown 
whether the use of WBRT would decrease the risk of leptomeningeal relapse.  
In conclusion, there is currenlty no high level of evidence in favour of SRS/SRT following 
surgery of brain metastases 
51
. 
 
Whole-brain radiotherapy  
Overall, in the different studies of the past a response following WBRT has been reported in 
up to 60% of patients; however, the neurological improvement could be partially attributable 
to steroids. Tumor volume reduction after WBRT has been associated with better 
neurocognitive function and prolonged survival 
52
. Median survival following WBRT alone in 
patients with multiple brain metastases ranges from 3 to 6 months, with 10%-15% of patients 
alive at 1 year. A meta-analysis of 39 trials has concluded that altered WBRT dose 
fractionation schemes are not superior in terms of overall survival, neurologic function or 
symptom control as compared to standard fractionation (30 Gy in 10 fractions or 20 Gy in 5 
fractions) (class I) 
53
. A recent phase III non inferiority trial in patients with brain metastases 
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from NSCLC, not candidate to either surgery or radiosurgery, has not shown differences in 
overall survival and quality of life between WBRT and supportive care (class I) 
54
.  
Up To date, radiosensitizers have not provided any clear additional benefit over conventional 
radiotherapy.  
Mild to severe cognitive dysfunctions occur following WBRT, and new approaches 
(neuroprotective drugs, new techniques of radiotherapy) are being developed in order to 
minimize the potential negative impact of WBRT.   
In a randomized double-blind, placebo-controlled phase III trial (RTOG 0614) the use of 
memantine, a neuroprotective compund,  during and after WBRT has resulted in better 
cognitive function over time, specifically delaying time to cognitive decline, and reducing the 
rates of decline in memory, executive function and processing speed (class IIa)
55
. 
Hippocampal avoidance WBRT (HAWBRT) using intensity modulated radiotherapy (IMRT) 
to reduce the radiation dose to the hippocampus
56
 is not associated with increased risk of 
recurrence in the low dose region 
57
. A single arm phase II trial (RTOG 0933) has suggested 
that the hippocampal avoidance may be associated with some sparing of WBRT-induced 
memory deficit and QoL (class IIb)
58
, but these findings need confirmation in randomized 
trials currently underway.  
 
Treatment of recurrent brain metastases 
Reoperation has been suggested to yield a neurological improvement and prolongation of 
survival in patients with locally accessible brain relapse, high performance status, stable 
extracranial disease and relatively long time to recurrence (˃ 6 months) (class IIIb)7. Salvage 
SRS after WBRT has been widely used (class IIIb)
59-61
. In a large retrospective series 
61 
the 
median time to in-field and distant brain failure from salvage SRS were 14 months and 11.7 
months, respectively, with a median time to CNS death of 9.31 months. 
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Reirradiation with SRS after local recurrence of an initial SRS has been employed in a limited 
number of patients, and the risk of long-term radionecrosis should be balanced  against the 
potential but unproven clinical benefit 
62
. 
Multiple courses of SRS for new brain metastases after an initial course of SRS with continue 
deferral of WBRT could yield high rates of local control, low risk of toxicity, and favorable 
duration of overall and neurologic progression-free survival 
63
. A recent large retrospective 
series has reported that in patients undergoing multiple courses of SRS the aggregate volume, 
but not the cumulative number of brain metastases, and the GPA score, as recalculated at the 
second course of SRS, correlate with duration of survival (class IIIb) 
64
.  
 
Chemotherapy and targeted therapies 
General considerations 
The level of evidence of studies on chemotherapy of brain metastases from solid tumors is 
class IIIa-b 
65
. Response rates reflect the sensivity of the primary tumor: relatively high 
response rates in SCLC (30-80%), intermediate rates in breast cancer (30-50%) and NSCLC 
(10-30%), and low rates in melanoma (10-15%); response in the brain does not always parallel 
that at the extracranial sites; the response to chemotherapy from most chemosensitive tumors 
could be of the same order of that observed after radiotherapy.  
The association of radiotherapy and chemotherapy may improve response rates compared with 
radiotherapy alone, but does not improve survival.  
As for targeted therapies and immunotherapy, due to the increasing number of reports in the 
recent literature, the review and grading of evidence were restricted to clinical trials focused 
on brain metastases (mainly phase II trials).  
Overall, the response rates of brain metastases to targeted agents in the different molecular 
subtypes seem higher than those observed after cytotoxic chemotherapy. However, the 
majority of targeted agents, that have been investigated so far, are small molecules, such as the 
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first-generation of tyrosine kinase inhibitors (TKTs), with a limited penetration of the blood-
brain barrier (BBB), as they are substrates of active efflux transporters. Changing the schedule 
and/or regimen of administration (for instance pulsatile dosing of the EGFR inhibitor erlotinib) 
could increase the efficacy. Two factors limit the impact of the available targeted agents on 
brain metastases: an unpredictable lack of molecular concordance between the primary tumor 
and the brain metastases, and the rapid emergence of a secondary resistance, that can occur 
systemically but not necessarily in the CNS. To overcome all these limitations, several second- 
and third-generation small-molecule inhibitors are being investigated. 
Last, there are numerous reports on the combination of immunotherapy and targeted therapies 
with SRS, but the literature on this issues is still too sparse 
66,67
. In this regard, an increased 
risk of radionecrosis following SRS and immunotherapy has been suggested
68
. 
 
Brain metastases from NSCLC 
Platinum compounds (cisplatin, carboplatin), alone or in combination with other agents 
(etoposide, vinorelbine, pemetrexed) are the most commonly used chemotherapeutics in the 
management of disseminated NSCLC, and have been employed in the setting of brain 
metastases, either upfront or at recurrence after radiotherapy
65
. The activity in terms of 
response rate is similar to that expected in the systemic setting, and is higher in chemonaive 
patients.   
Targeted agents in patients with sensitizing EGFR and ALK mutations have shown activity. 
Response rates of brain metastases to EGFR TKI treatment (gefinitib, erlotinib, and afatinib) 
in patients with NSCLC harboring EGFR mutations reach 60%-80%, with rates of complete 
responses as high as 40%. Median OS is in the range of 15-20 months, and PFS in the brain is 
about 6.6 months-11.7 months, both significantly longer than for EGFR wild-type tumors
69
.   
Based on the high intracranial response rates TKIs alone have been proposed as initial 
treatment instead of WBRT in patients harboring activating EGFR mutations and 
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asymptomatic brain metastases
70-72
, although this approach could be associated with a higher 
risk of subsequent intracranial relapse. The use of primary TKIs can avoid the adverse effects 
of WBRT although it is unlikely to avoid the need for subsequent WBRT. An alternative 
strategy is the use of cranial radiotherapy (SRS or WBRT) in combination with TKIs, which 
may improve PFS and OS compared with TKIs alone or radiotherapy with or without 
chemotherapy, although this is somewhat controversial and remains to be proven (class IIIa 
and b) 
73,74
. A phase II study from China has resported that the combination of WBRT and 
erlotinib has a tolerable toxicities, and suggested a prolonged PFS and OS (class IIb) 
75
. 
Conversely,  phase II (class IIa and b) 
76,77
 and III (class I) 
78
 trials in patients with NSCLC 
brain metastases not enriched for EGFR mutations failed to demonstrate a superiority of the 
combination of erlotinib with either SRS or WBRT over radiotherapy alone with a suggestion 
of worse outcome in patients receiving the combined therapy. A Chinese phase II trial of 
WBRT with concurrent icotinib, another EGFR inhibitor, has suggested that the combination 
could improved survival compared with historical controls 
79
. 
Other druggable alterations in NSCLC patients are the rearrangements of the “anaplastic 
lymphoma kinase” (ALK) gene, that seem to be constant between brain metastasis and 
primary tumor 
80
. NSCLC with ALK activating translocations is sensitive to treatment with the 
ALK inhibitor crizotinib. In a retrospective analysis of the clinical trial PROFILE crizotinib 
has been associated with 55% intracranial control at 3 months of therapy in patients with ALK 
rearranged NSCLC, who were ALK inhibitor-naïve and had brain metastases 
81
. Crizotinib 
yielded 18%-33%  responses using RECIST  criteria and the efficacy was observed among 
both radiotherapy-naïve and preirradiated patients (class IIIb). Responses are generally short-
lived, and most patients need subsequent WBRT. Whether WBRT should be employed 
immediately after crizotinib response or after progression is still unclear. A recent 
multiinstitutional retrospective analysis has suggested that patients with brain metastases from 
ALK-rearranged NSCLC receiving radiotherapy (SRS and/or WBRT) and ALK inhibitors 
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(crizotinib, ceritinib, alectinib) have a prolonged overall survival (around 49.5 months) (class 
IIIb) 
82
. 
Some efficacy with acceptable safety has been suggested in a phase II study of patients with 
asymptomatic untreated brain metastases from NSCLC with bevacizumab in combination with 
paclitaxel and carboplatin (class IIb) 
83
. 
A recent early analysis of a phase II trial of the PD-1 inhibitor pembrolizumab has shown 
activity in untreated or previously irradiated brain metastases from NSCLC 
84
, but the trial is 
still ongoing. 
 
Brain metastases from breast cancer  
Chemotherapy regimens, variably combining capecitabine, cyclophosphamide, 5-FU, 
methotrexate, vincristine, cisplatin, etoposide, are active in patients with brain metastases from 
breast cancer 
65
.  
The dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib has shown modest activity in a 
phase II study in HER2+ breast cancer patients with brain metastases following trastuzumab-
based systemic chemotherapy and WBRT (class IIb) 
85
. CNS objective responses to lapatinib 
were observed in 6% of patients and 21% experienced ≥ 20% volumetric reduction in the CNS 
lesions. Another phase II single arm study (LANDSCAPE) has shown that the association of 
lapatinib and capecitabine in patients with radiotherapy-naïve brain metastases from HER-
positive metastatic breast cancer yields durable responses in up to 65% of patients (class IIb)
86
. 
A single arm phase II trial on neratinib (HER2 TKI inhibitor) in patients with brain metastases, 
previously treated with either WBRT or SRS, has shown a response rate of 8% with an OS of 
8.7 months (class IIb) 
87
. 
Due to a lack of prospective trials, it is not clear whether trastuzumab, that probably can cross 
a more permeable BBB within established brain metastases, can be active as well 
88
. Several 
case reports and small patient series indicate that the antibody-drug conjugate T-DM1 may be 
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active against brain metastases of HER 2-positive breast cancer (class IV) 
89,90
. Few data only 
are available on the combination of different anti-HER 2 agents. There are no reliable data on 
the efficacy of endocrine therapies. 
 
Brain metastases from melanoma 
Fotemustine (response rate of 5-25%) and temozolomide (response rate 6-10%), either as 
single agent or in combination with WBRT, are active agents against brain metastases from 
melanoma
65,91
.  
Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), that potentiates the antitumor immune response. Despite the 
fact that ipilimumab does not cross the BBB, the activation of the immune system and the 
migration of lymphocytes into the brain allow an antitumor effect also in the brain 
parenchyma
92
. In a phase II study of ipilimumab in metastatic melanoma 12 of 115 patients 
had brain metastases at enrollment 
93
.Two of these patients achieved PR and three had stable 
disease (SD). Both patients with PR and one with SD had an overall survival of over 4 years.  
In a retrospective analysis of 38 patients with brain metastases treated within the French 
Expanded Access Program (EAP), 3 had PR and 5 SD, and 1-year survival was 10.5% 
94
. An 
open-label, single-arm phase 2 trial included two cohorts of patients, 51 patients with 
asymptomatic brain metastases (cohort A) and 21 patients with symptomatic brain metastases 
controlled with corticosteroids (cohort B) (class IIb) 
95
. Disease control (CR+PR+SD) after 12 
weeks was 26 % in cohort A and 10 % in cohort B, with median OS of 7.0 months and 3.7 
months, respectively.  The response rates were similar for intra- and extracranial disease in 
both cohorts, and neurological toxicity was mainly of grade 1-2. A single arm phase 2 study, 
the NIBIT-M1-study, treated with ipilimumab and fotemustine 86 patients of whom 20 had 
asymptomatic brain metastases at baseline, mostly oligometastases 
96
: 10 of these patients 
achieved disease control, and median PFS and OS were 4.5 months and 13.4 months, 
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respectively. In an Expanded Access Program (EAP) of stage 3 and 4 melanoma and 
asymptomatic brain metastastes failing or not tolerating other treatments 
97
, ipilimumab 
yielded a control rate of 27%, including 4 patients with a complete response and 13 with a 
partial response. Median progression-free survival and overall survival were 2.8 and 4.3 
months, respectively, and approximately one-fifth of patients were alive 1 year after starting 
ipilimumab. 
Chemotherapy 
96
 or radiotherapy 
98
 could induce a release of tumour antigens, thus increasing 
the antitumor activity of ipilimumab. An abscopal effect has been seen in melanoma patients, 
in whom radiotherapy for one lesion induced a shrinkage of non-irradiated lesions 
99
. 
Sequence and timing of radiotherapy in relation to ipilimumab have not been fully 
elucidated
100,101
.  To sum up, immunotherapy with ipilimumab has activity in brain metastases 
from melanoma, and the effects seem similar in intra- and extracranial disease. In patients with 
symptomatic brain metastases, the effect is smaller, maybe due to the corticosteroid treatment 
or alternatively the general worse prognosis. An activity of PD-1 inhibitors, such as 
pembrolizumab or nivolumab, in brain metastases from melanoma has been suggested
84,102
.  
BRAF-mutations occur in approximately 50% of melanomas, resulting in a constitutive 
activation of the mitogen-activated protein kinase (MAPK) pathway, and the BRAF mutation 
status is usually concordant betweent extracranial tumor  and brain metastasis 
103
.  The BRAF-
inhibitor vemurafenib has documented activity in brain metastases from BRAF-mutated 
melanomas 
104
. An open-label pilot study included 24 patients with BRAF-mutated advanced 
melanoma and symptomatic brain metastases (class IIIa)
105
. All patients were on 
corticosteroids for symptom control, and had progressed after previous surgery or 
radiotherapy. Of 19 patients with measurable intracranial disease, 3 had a PR and 13 a stable 
disease. Median duration of response in the brain was 4.4 months with median OS of 5.3 
months. In a retrospective review of 22 patients with asymptomatic brain metastases (class 
IIIb) 
106
 a 50% response rate was seen regardless of whether they had previous local therapy to 
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the brain or not, and clinical benefit was reported for two thirds of patients. Median time to 
progression (TTP) and median OS were 23 and 46 weeks for patients with objective response, 
and 12 weeks and 21 weeks for patients without objective response, respectively.  
Two studies are available on the other BRAF inhibitor dabrafenib. A phase 1 study included 
10 patients with asymptomatic, untreated brain metastases, and 9 achieved a decrease in the 
size of brain lesions and 4 achieved a CR (class IIIb) with a median PFS of 4.2 months 
107
.  
The multicenter, open-label, phase 2 BREAK-MB trial enrolled 172 patients with 
asymptomatic, untreated (cohort A) or progressive (cohort B) brain metastases in melanoma 
patients with V600E or V600K mutation for treatment with dabrafenib (class IIb)
108
. Over 
80% of patients in both cohorts with V600E mutations had intracranial disease control 
(CR+PR+SD), median PFS was longer than 16 weeks in both cohorts, and OS exceeded 31 
weeks.The combination of BRAF inhibitors and SRS could improve survival 
109,110
, but an 
increase of toxicities could occur. A superior efficacy of copmbination therapies (BRAF and 
MEK inhibitors, nivolumab abd ipilimumab) is emerging in metastatic melanoma 
111
, but there 
are no data on brain metastases thus far. 
 
 
 
Renal Cell Carcinoma 
Some retrospective series have described responses of brain metastases to sunitinib 
112,113
 
mostly in patients with small, asymptomatic metastases. In an opel label EAP sunitinib 
displayed a response rate of 12%, with PFS and OS of  5.6 months and 9.2 months, 
respectively (class IIIb) 
112
. In another recent retrospective series on the efficacy of targeted 
therapies (sunitinib in 41 of 65 patients) a median OS of 12.2 months was observed (class 
IV)
114
. Conversely, in a small phase II study  of 16 patients with untreated brain metastases 
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receiving sunitinib, 5 patients had SD only 
115
. A synergism between targeted therapies and 
SRS has been suggested 
116
.  
 
Supportive care: This section can be found in the Supplementary material. 
 
Conclusion  
Our Guidelines represent the state of knowledge at the time of writing. The European Association 
of Neuro-Oncology Website will provide future updates of these Guidelines.  
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Table 1. Search strategy and selection criteria 
 A Task Force was appointed in 2014 by the European Association of Neuro-Oncology (EANO) to 
draw Guidelines on the management of brain metastases from solid tumors. The Task Force was 
composed of medical experts from 10 European countries, including neurologists, neurosurgeons, 
radiation oncologists, medical oncologists, neuroradiologists and neuropathologists. 
 References were identified through searches of PubMed, using specific and sensitive keywords, as 
well as combinations of keywords. Abstracts presented at American Society of Clinical Oncology 
in 2014 and 2015 were considered as well when relevant. When available we also collected existent 
guidelines from national multidisciplinary neuro-oncological societies. The final reference list was 
generated on the basis of originality and relevance to the scope of this review. The last update on 
PubMed was on July 15
th
, 2016.  
 Scientific evidence was assessed and graded according to the following categories: class I evidence 
was derived from randomized phase 3 clinical trials; class IIa evidence derived from randomized 
phase 2 trials; class IIb evidence derived from single arm phase 2 trials; class IIIa evidence derived 
from prospective studies, including observational studies, cohort studies, and case-control studies; 
class IIIb evidence derived from retrospective studies; and class IV evidence derived from 
uncontrolled case series, case reports, and expert opinions.  
 To establish recommendation levels, the following criteria were used: level A required at least one 
class I study or two consistent class IIa studies; level B required at least one class IIa study or 
several class IIb and III studies; level C required at least two consistent class III studies. When there 
was insufficient evidence to categorize recommendations in levels A-C we classified the 
recommendations as a Good Practice Point, if agreed by all members of the task force. 
When drawing recommendations, at any stage, the differences were resolved by discussions and, if 
persisting, were reported in the text. 
Table 2. Recommendations at diagnosis  
 When neurological symptoms and/or signs develop in a patient with known solid cancer, brain 
metastasis must always be suspected. (Good Practice Point). 
 Contrast-enhanced MRI is the method of choice for assessment of brain metastases. A differential 
diagnosis between brain metastases and primary brain tumors (especially malignant gliomas and 
PCNSLs) and nonneoplastic conditions (abscesses, infections, vascular diseases) must be 
considered, even in patients with history of solid cancer and/or multiple lesions (Good Practice 
Point). 
 Diffusion-weighted MR imaging is useful to differentiate among ring-enhancing lesions brain 
metastases from pyogenic abscesses (level C). 
 Advanced neuroimaging techniques, such as MRI perfusion, MR spectroscopy, PET with FDG or 
amino acids, do not provide sufficient differentiation among enhancing lesions between brain 
metastases and other malignant brain tumors of glial or non-glial origin (Good Practice Point). 
 In case of known primary tumor, systemic staging should include all the assessments required for 
the specific tumor type in order to define the activity of the primary lesion and the existence of 
extra cranial metastases (Good Practice Point). 
 In case of unknown primary tumor a thorough physical examination (including testes and skin 
inspection), CT of the chest/abdomen, and mammography and/or ultrasound of breast are 
recommended and, if negative, whole body FDG PET is recommended (Good Practice Point). 
 A tissue diagnosis is mandatory in patients with suspected brain metastasis on MRI and unknown 
primary tumor after a systemic workup before any treatment is undertaken (Good Practice Point). 
 A tissue diagnosis should be considered in patients with well controlled systemic cancer when the 
neuroimaging appearance is atypical and/or a long interval has elapsed since the initial cancer 
diagnosis (Good Practice Point).  
 Routine hematoxylin-eosin stain of the biopsy specimen usually is sufficient for a correct 
histological diagnosis. Immunohistochemical markers are required when the basic morphology is 
equivocal and/or the primary  tumor is unknown in order to suggest the site of origin (Good 
Practice Point). 
 Molecular markers that influence treatment decisions (predictive markers) should be assessed 
from brain metastasis tissue, if available, even when the respective marker(s) have already been 
assessed from tissue samples from extra-cranial tumor manifestations (Good Practice Point) 
 CSF biochemistry and cytology are needed when a coexistent leptomeningeal involvement is 
suspected (Good Practice Point).  
 Before treatment, patients should be assessed according to one of the existing prognostic scores 
(with preference for GPA score) (Good Practice Point). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Recommendations regarding treatment of newly diagnosed brain metastases. 
  Surgical resection should be considered in patients with a limited number (1 to 3) of newly 
diagnosed brain metastases, especially in case of lesions of ≥ 3 cm in diameter (symptomatic or 
not), lesions with necrotic or cystic appearance and edema/mass effect, lesions located in the 
posterior fossa with associated hydrocephalus, and lesions located in symptomatic eloquent areas 
(Good Practice Point). 
 Surgical resection is recommended when the systemic disease is absent/controlled and the 
Karnofsky Performance score is 60 or more, as it can prolong survival (level A). 
 Surgical resection can be an option when the systemic disease is active but effective systemic 
treatment options are available or when the primary tumor is relatively radioresistant (i.e. 
melanoma, renal carcinoma, colon carcinoma) (Good Practice Point). 
 Stereotactic radiosurgery should be considered in patients with metastases of a diameter of ≤ 3-
3.5 cm (level B). 
 Stereotactic fractionated radiotherapy (SFRT) should be considered in patients with metastases 
larger than 3 cm in maximum diameter and a larger irradiation volume than 10 or 12 ccm due to 
increased toxicity and radiation necrosis of normal brain tissue (Good Practice Point). 
 Stereotactic radiosurgery and/or stereotactic fractionated radiotherapy should be considered in 
patients with metastases that are not resectable due to location (i.e. basal ganglia, brain stem, 
eloquent cortical areas) or with comorbidities precluding surgery (i.e. older age, cardiovascular 
disease, etc) (Level C). 
 When both surgical resection and SRS/SFRT are feasible, the choice should be made on a case-
by-case basis with consideration given to tumor size, site, type of neurological symptoms, need 
for steroids, patient preference and/or physician expertise (Good Practice Point). 
 Following complete surgical resection or SRS for a limited number of brain metastases, adjuvant 
WBRT is not unequivocally recommended due to lack of a survival advantage and risk of 
neurocognitive dysfunctions (level A). 
 When withholding adjuvant WBRT following complete surgical resection or SRS, a close 
monitoring with MRI (every 3-4 months) is recommended (Good Practice Point). 
 When withholding adjuvant WBRT after surgical resection of brain metastases postoperative 
stereotactic radiosurgery or stereotactic frationated radiotherapy to the resection cavity should be 
given to maintain and increase local control (Level C). As the post-resection cavity volume is 
usually smaller than pre-resection metastasis volume, it is recommended to perform a 
postoperative dedicated brain MRI for the SRS/SFRT, while the timing appears not to be relevant 
(Good Practice Point).  
  When employing initial WBRT, a monitoring of cognitive functions with specific batteries is 
recommended (Good Practice Point). 
 The decision regarding whether to employ SRS, SFRT, WBRT, alone or in combination, for 
patients with multiple brain metastases comes down to clinical discretion, patient preference and 
logistical considerations with the absolute number of brain metastases becoming less crucial 
(Good Practice Point). 
 WBRT or best supportive care should be considered for patients with short life expectancy  (low 
KPS score and/or progressive systemic disease) (level B). 
 
 
 
 
 
Table 4. Recommendations regarding treatment of recurrent brain metastasis  
 Surgery can be an option in selected patients with favorable prognostic factors (younger age, high 
performance status, controlled systemic disease) and accessible location or when a differential 
diagnosis between tumor regrowth and radionecrosis (especially following SRS) is required 
(level C). 
 Salvage SRS following initial WBRT can be an option in terms of local tumor control and 
survival (level C). 
 Multiple courses of SRS for new brain metastases after an initial course of SRS can represent an 
alternative to WBRT (level C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Recommendations regarding medical therapy 
 Conventional chemotherapy may be the initial treatment for patients with brain metastases from 
chemosensitive tumors, like SCLC or breast cancer, especially when small and/or asymptomatic 
(Good Practice Point). 
 No targeted agents are currently registered for the treatment of brain metastases from any solid 
tumors (Good Pratice Point). 
 Patients with brain metastases from NSCLC harboring activating EGFR mutations or ALK 
rearrangements can derive benefit from the use of specific TKIs inhibitors (level C). 
 Continuous HER2 blockade should be offered to patients with CNS metastases of HER2 positive 
breast cancer (Good Practice Point). 
 Patients with brain metastases from HER2 positive breast cancer can derive benefit from the use 
of lapatinib, alone or associated with capecitabine (level C). 
 Patients with melanoma and brain metastases can derive benefit from targeted agents either 
ipilimumab or BRAF inhibitors (level C). 
 Patients with renal cell carcinoma and brain metastases can derive benefit from multitarget TKIs, 
in particular sunitinib (Good Pratice Point). 
 Overall, while SRS or WBRT remain the mainstay of initial therapy, in selected patients with 
asymptomatic and small brain metastases targeted agents may be a reasonable option for an 
upfront treatment  (Good Practice Point). 
 Ultimately, patients with solid tumors and brain metastases should be encouraged to participate 
into clinical trials with targeted agents, when available (Good Practice Point). 
 Pausing of treatment with a novel systemic agents during radiotherapy to the brain should be 
considered to minimize the risk of unexpected toxicities (Good Practice Point) 
 
Table 6. Recommendations regarding supportive care  
 For symptomatic patients dexamethasone is the corticosteroid of choice and a twice-daily dosing 
is sufficient. Total daily doses range between 4 mg and 32 mg (Good Practice Point). 
 An attempt to reduce the dose of steroids in order to minimize side effects from chronic steroids 
administration, should be undertaken once the maximum neurological improvement has been 
obtained (Good Practice Point). 
 Asymptomatic patients do not need steroids, while steroids may reduce the acute or subacute side 
effects of WBRT or SRS (Good Practice Point). 
 Anticonvulsants should not be prescribed prophylactically (level A). 
 In patients who suffer from seizures and need a concomitant treatment with chemotherapeutics or 
targeted agents, enzyme-inducing antiepileptic drugs should be avoided (level B). 
 In patients with venous-thrombo-embolism (VTE), low-molecular-weight-heparin (LMWH) is 
effective and well tolerated for both initial therapy and secondary prophylaxis (level A). A 
duration ranging from 3 to 6 months is recommended for the anticoagulant treatment (Good 
Practice Point); however, there are some data supporting longer use in patient with active 
malignancies and those with recurrence despite therapy.  Prophylaxis in patients undergoing 
surgery is recommended (level B recommendation). 
 Bevacizumab treatment can be considered for symptomatic radionecrosis (Good Practice Point). 
 
 
 
SUPPLEMENTARY MATERIAL 
 
Diagnosis by neuroimaging  
Contrast-enhanced MRI is more sensitive than enhanced CT (including double-dose delayed 
contrast) or unenhanced MRI in detecting brain metastases, particularly lesions in the posterior 
fossa or multiple punctate metastases 
1,2
. Although T2-weighted and FLAIR images are sensitive in 
showing vasogenic edema as areas of increased signal intensity, not all metastatic lesions have 
sufficient edema to be identified.  
There are no specific features on MRI that distinguish brain metastases; however, a peripheral 
location, spherical shape, ring enhancement with prominent peritumoral edema and multiple lesions 
all suggest metastatic disease a restricted diffusion in abscesses compared to unrestricted diffusion 
in necrotic glioblastomas or metastases, but the findings are not specific 
3-5
. When employing MR 
perfusion imaging there is a tendency of lower cerebral blood volume values within the peritumoral 
region in brain metastases compared with glioblastomas 
6,7
. MR spectroscopy in the peritumoral 
region more often shows a cholin to creatinin ratio lower in brain metastases compared with high 
grade gliomas
8,9
. FDG PET and 18F-FET PET do not provide sufficient differentiation between 
metastases and high grade glial tumors 
10,11
. 
 
Staging  
When a brain mass is suspected to be a brain metastasis but there is not a prior history of cancer, it 
is not clear how far to pursue the systemic investigation. As in most cases the primary tumor is 
located in the lung 
12,13
, a chest CT is always recommended. CT of the abdomen occasionally shows 
an unsuspected cancer. Further search for a primary tumor is almost never fruitful without positive 
features in the patient’s history or localizing signs on the physical examination to suggest a specific 
primary site 
14
. Whole-body fluorodeoxyglucose (FDG) PET is a sensitive tool for detecting a 
“probable” primary tumor by visualizing foci of abnormal uptake, more often in the lung 15, but the 
specificity in differentiating malignant tumors from benign or inflammatory lesions is relatively 
low. Regarding brain metastases from an undetected primary site after the first staging, it has been 
shown that, when performing serial CT of thorax during the follow-up in asymptomatic patients, 
the primary tumor in the lung (a non small-cell carcinoma in the majority) may be discovered in 
almost all patients, but few of them only benefit in terms of survival from an early detection and 
treatment 
16
. Therefore, a costly extensive evaluation for the undetected primary during the follow-
up is not appropriate until more effective cancer therapies are available 
14,16
. 
 
Diagnostic neuropathology 
Cerebral metastasis of known primary tumors 
In the situation of a patient with a known primary tumor, the histology and the marker profile of the 
primary and the cerebral metastasis will usually show similarities. However, the histologic 
comparison between the specimen of primary tumor and cerebral metastasis is important, as not 
infrequently patients may suffer from more than one tumor, and the metastasis may have originated 
from another primary than supposed.  
Cerebral metastasis of unknown primary tumors. 
For the determination of the lineage of the metastatic tumor, basic morphology will provide a first 
differentiation between carcinomas, lymphomas or melanomas. In addition, immunohistochemical 
profiles of metastases may be indicative of the site and lineage of the primary tumor 
17
; however, 
they show variable overlap, and most markers are not specific. In case of a cerebral 
adenocarcinoma of unknown primary TTF-1 positivity is strongly associated with lung cancer and 
cancer of the thyroid. Negativity for CK7 and positivity for CK20 hints to colorectal cancer. Neuro-
endocrine differentiation is tested by chromogranin, synaptophysin and antibodies directed against 
specific hormones (insulin, gastrin, glucagon, serotonin and somatostatin). Further, there are 
immunohistochemical panels for mesenchymal tumors (vimentin, desmin, S100). 
Attempts to identify unknown primary tumors from their metastases by using RNA expression 
profiles are ongoing. In general, few studies have focused on the comparison of primary tumors and 
their cerebral metastases with respect to lineage markers and biomarkers for treatment 
eligibility
18,19
.  
Recent studies have emphasized the genetic and phenotypic heterogeneity in cancer metastases and 
its impact on targeted therapies resistance  
20,21
. The interest of the molecular characterization of 
brain metastatic disease is to document a potential phenotypic heterogeneity that could assist 
physicians in defining the therapeutic strategy. Indeed, biological documentation of metastatic 
disease is an approach that can lead to a change of the cerebral local treatment, but also to change 
the systemic treatment strategy 
22
. 
 
Supportive care 
Two evidence-based guidelines on the role of steroids to control vasogenic edema and mass effect 
in brain metastases are available in Europe 
23
 and US 
24
. Dexamethasone is the steroid of choice 
because its minimal mineralocorticoid effect and long half-life, although any other corticosteroid 
can be effective if given in equipotent doses. A neurological improvement within 24-72 h after 
beginning of treatment is to be expected in up to 75% of patients with a dose effect relationship 
25
.  
The need for anticonvulsant medication is clear in patients who have experienced a seizure while 
the evidence does not support prophylaxis with antiepileptic drugs (AEDs) in patients with brain 
tumors, including metastases. Twelve studies, either randomized trials or cohort studies, 
investigating the ability of prophylactic AEDs (phenytoin, phenobarbital, valproic acid) to prevent 
the first seizure, have been examined, and none have demonstrated efficacy (class I) 
26
. 
Subtherapeutic levels of anticonvulsants were extremely common and the severity of side effects 
appeared to be higher (20–40%) in brain tumor patients than in the general population receiving 
anticonvulsants, probably because of drug interactions. Phenytoin, phenobarbital, carbamazepine 
and oxcarbazepine stimulate the cytochrome P450 system and accelerate the metabolism of 
corticosteroids and antineoplastic agents, such as nitrosoureas, paclitaxel, cyclophosphamide, 
topotecan, irinotecan, thiotepa, adriamycin, methotrexate, imatinib, gefitinib, erlotinib and other 
tyrosine kinase inhibitors (TKIs), and thus reduce their efficacy. The role of prophylactic 
anticonvulsants remains to be addressed in some subgroups of patients who have a higher risk of 
developing seizures, such as those with metastatic melanoma, hemorrhagic lesions or multiple 
metastases. For patients who underwent a neurosurgical procedure the efficacy of prophylaxis has 
not been proven. The efficacy of novel AEDs (levetiracetam, topiramate, gabapentin, lamotrigine, 
lacosamide) has not been extensively investigated so far. 
Anticoagulant therapy is the standard treatment for acute venous thromboembolism (VTE) in 
cancer patients. Subcutaneous low-molecular weight heparin (LMWH) is recommended for deep 
vein thrombosis and pulmonary embolism as well as for long-term secondary prophylaxis (class I) 
27
. Anticoagulant therapy may increase the risk of intratumoral bleeding for brain metastases, 
especially for melanoma primaries. There are limited data on the use of novel oral anticoagulants 
28
.  
 
References Supplementary Material 
1. Sze G, Milano E, Johnson C, et al. Detection of brain metastases: comparison of contrast-
enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol. 
1990;11(4):785-791.  
2. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in 
patients with brain metastases. J Neurooncol. 1999;44(39:275-281. 
3. Desprechins B, Stadnik T, Koerts G, et al. Use of diffusion-weighted MR imaging in 
differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. AJNR Am J 
Neuroradiol. 1999;20(7):1252-1257. 
4. Hartmann M, Jansen O, Heiland S, et al. Restricted diffusion within ring enhancement is not 
pathognomonic for brain abscess. AJNR Am J Neuroradiol. 2001;22(9):1738-1742. 
5. Duygulu G, Ovali GY, Calli C, et al. Intracerebral metastasis showing restricted diffusion: 
correlation with histopathologic findings. Eur J Radiol. 2010;74(1):117-1120. 
6. Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by 
using perfusion and proton spectroscopic MR imaging. Radiology 2002;22283):715-721. 
7. Bulakbasi N, Kocaoglu M, Farzaliyev A, et al. Assessment of diagnostic accuracy of perfusion 
MR imaging in primary and metastatic solitary malignant brain tumors. AJNR Am J 
Neuroradiol. 2005;26(9):2187-2199 
8. Chiang IC, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary 
metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion 
imagings. Neuroradiology 2004;4688):619-627. 
9. Server A, Josefsen R, Kulle B, et al. Proton magnetic resonance spectroscopy in the distinction 
of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol. 
2010;51(3):316-325. 
10. Kosaka N, Tsuchida T, Uematsu H, et al. 18F-FDG PET of common enhancing malignant brain 
tumors. AJR Am J Roentgenol. 2008;190(3):365-369. 
11. Hutterer M, Nowosielski M, Putzer D, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable 
diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol.  
2013;15(3):341-351. 
12. Le Chevalier T, Smith FP, Caille P, et al. Sites of primary malignancies in patients presenting 
with cerebral metastases. A review of 120 cases. Cancer 1985;56(4):880-882. 
13. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 
1989;149(5):1076-1080. 
14. Van de Pol M, van Aalst VC, Wilmink JT, et al. Brain metastases from an unknown primary 
tumor: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry. 
1996;61(39:321-323. 
15. Klee B, Law I, Højgaard L, et al. Detection of unknown primary tumors in patients with 
cerebral metastases using whole-body 18F-flouorodeoxyglucose positron emission tomography. 
Eur J Neurol. 2002;9(6):657-662. 
16. Rudà R, Borgognone M, Benech F, et al. Brain metastases from unknown primary tumor: a 
prospective study. J Neurol. 2001;248(5):394-398. 
17. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for 
identification of tissue of origin. Arch Pathol Lab Med. 2010;134(2):216-224.  
18. Berghoff AS, Bartsch R, Wöhrer A, et al. Predictive molecular markers in metastases to the 
central nervous system: recent advances and future avenues. Acta Neuropatol.  
2014;128(6):879-891. 
19. Shen Q, Sahin AA, Hess KR, et al. Breast cancer with brain metastases: clinicopathologic 
features, survival, and paired biomarker analysis. Oncologist. 2015;20(5):466-473. 
20. Almendro V, Kim HJ, Cheng YK, et al. Genetic and phenotypic diversity in breast tumor 
metastases. Cancer Res. 2014;74(5):1338-1348. 
21. Brastianos PK, Carter SL, Santagata S, et al. Genomic Characterization of Brain Metastases 
Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 
2015;5(11):1164-1177. 
22. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA 
sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial 
(SAFIR01/UNICANCER). Lancet Oncol. 2014;15(3):267-274. 
23. Soffietti R, Cornu P, Delattre JY, et al. EFNS Guidelines on diagnosis and treatment of brain 
metastases: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):674-681. 
24. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain 
metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 
2010;96(1):103-114. 
25. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on 
Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 
mg per day. Neurology. 1994;44(4):675-680. 
26. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in 
patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of 
the American Academy of Neurology. Neurology. 2000;54(10):1886-1893. 
27. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment 
in patients with cancer: american society of clinical oncology clinical practice guideline update 
2014. J Clin Oncol. 2015;33(6):654-656. 
28. Sardar P, Chatterjee S, Herzog E, et al. New Oral Anticoagulants in Patients With Cancer: 
Current State of Evidence. Am J Ther. 2015;22(4):460-468. 
 
 
 
